When doctors look for ways to predict how a patient might fare after a cancer diagnosis, they look for markers that signal how aggressive a disease is. A review of 22 studies involving patients with solid tumors found that the PTTG1 protein acts as a significant indicator of how the disease progresses.
Patients with high levels of this protein showed significantly worse overall survival compared to those with low levels. The data also showed much poorer disease-free and recurrence-free survival for these patients. This means that when PTTG1 is high, the cancer is more likely to return or stay active in the body.
High PTTG1 levels were also linked to more advanced stages of cancer, including larger tumors and the spread of cancer into lymph nodes or other parts of the body. While this protein shows a clear link to poorer outcomes in cancers like lung, breast, and kidney cancer, it is an association rather than a proven cause of the disease.
